abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 08월 28일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

The development of PET imaging agents for diagnosis of Alzheimer’s disease

등록일
2008년 8월 12일 11시 05분 19초
접수번호
1169
발표코드
목18G1심 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 14시 : 00분
발표형식
심포지엄
발표분야
의약화학 - Recent Drug Development of Neurodegenerative Disease
저자 및
공동저자
김동진
한국과학기술연구원 케모인포매틱스연구단, Korea
Alzheimer’s disease (AD) is pathologically characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. Such plaques can be excellent targets for in vivo brain imaging of AD patients as an early diagnosis of AD. Development of imaging probes for direct marking of beta-amyloid aggregates in the living brain is a highly active research area in recent years. For instance, Pittsburgh compound B (PIB), a derivative of Thioflavin T with high binding affinity to beta-amyloid fibrils, is the most common imaging agent used in investigational studies of AD via positron emission tomography (PET). In this study a novel series of 2,3-dihydroisoindol-1-one and 1,3-dione derivatives for beta-amyloid specific binding agents is described. Thirty cold compounds for a binding study, were synthesized and evaluated by a competitive binding assay with [125I]TZDM against beta-amyloid aggregates. Most of the synthesized compounds displayed higher binding affinities, with Ki value in the subnanomolar range (0.16-1.05 nM), than PIB (Ki = 0.77 nM). Novel synthesized [11C]- and [18F]-labeled isoindole derivatives were evaluated as potential beta-amyloid imaging agents based on their in vivo pharmacokinetic studies using micro-PET. Most of the radio-labeled compounds showed high brain uptake and excellent clearance in normal mice. The results suggest that these [11C]- and [18F]-labeled compounds are potential PET imaging probes for studying accumulation of beta-amyloid fibrils in the brains of AD patients.

상단으로